Radiotherapy & Oncology
Volume 92, Issue 1 , Pages 42-47 , July 2009

Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer

  • Valérie Fonteyne

      Affiliations

    • Department of Radiotherapy, Ghent University Hospital, Belgium
    • Corresponding Author InformationCorresponding author. Address: Department of Radiotherapy, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium.
    • ,
  • Geert Villeirs

      Affiliations

    • Department of Radiology, Ghent University Hospital, Belgium
    • ,
  • Nicolaas Lumen

      Affiliations

    • Department of Urology, Ghent University Hospital, Belgium
    • ,
  • Gert De Meerleer

      Affiliations

    • Department of Radiotherapy, Ghent University Hospital, Belgium

Received 6 May 2008 ,Revised 4 March 2009 ,Accepted 7 March 2009.

References 

  1. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  2. Jang TL, Bekelman E, Liu Y, et al. Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP). JCO. 2007;25:S6506
  3. Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU Int. 2006;97:955–962
  4. Jereczek-Fossa BA, Vavassori A, Fodor C, et al. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients. Int J Radiat Oncol Biol Phys. 2008;71:784–794
  5. Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int. 2005;96:43–47
  6. Chen R, Clark J, Manola J, Talcott JA. Treatment ‘mismatch’ in early prostate cancer: do treatment choices take patient quality of life into account?. Cancer. 2008;112:61–68
  7. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:614–623
  8. Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol. 2007;84:156–163
  9. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiation therapy as primary therapy for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004;60:777–787
  10. De Meerleer GO, Fonteyne VH, Vakaet L, et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol. 2007;82:160–166
  11. Bolla M, Gonzalea D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  12. Gottschalk AR, Roach M. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer. 2004;90:950–954
  13. De Meerleer G, Villeirs GM, Vakaet L, Delrue LJ, De Neve WJ. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer. Strahlenther Onkol. 2004;180:573–581
  14. De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000;47:639–648
  15. De Meerleer G, Vakaet L, De Gersem W, Villeirs G, De Neve W. Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol. 2004;180:136–143
  16. Diaz A, Roach M, Marquez C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;30:323–329
  17. Vandecasteele K, De Neve W, Villeirs G, et al. Accuracy of ultrasound-guided prostate cancer (UGPP). Radiother Oncol. 2004;73:S410
  18. Jacobsen NE, Moore KN, Estey E, Voaklander D. Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates. J Urol. 2007;177:615–619
  19. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65–70
  20. Muren LP, Wasbo E, Helle SI, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol Biol Phys. 2008;71:1034–1041
  21. Heymann JJ, Benson MC, O’Toole KM, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25:77–84
  22. Kitamura K, Shirato H, Shinohara N, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor tracking system for prostate cancer: preliminary results of a phase I/II study. Cancer J. 2003;9:268–276
  23. Soete G, Arcangeli S, De Meerleer G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiat Oncol. 2006;80:78–81
  24. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  25. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionation intensity-modulated radiotherapy (70Gy at 25Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  26. Brabbins D, Martinez A, Yan D, et al. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Int J Radiat Oncol Biol Phys. 2005;61:400–408
  27. Nichol A, Chung P, Lockwood G, et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3-D conformal radiotherapy. Radiat Oncol. 2005;76:11–17
  28. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  29. Su AW, Jani AB. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol. 2007;30:215–219
  30. Pontvert D, Gaboriaud D, Flam T, et al. Conformal radiotherapy to 76Gy in localized prostate cancer therapeutic modalities and preliminary results. Cancer Radiother. 2008;12:78–87
  31. McCloskey SA, Ellerbroek NA, McCarthy L, et al. Treatment putcomes of three-dimensional conformal radiotherapy for localized prostate carcinoma. Cancer. 2004;101:2693–2700
  32. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  33. Vora SA, Wong WW, Schild SE, Ezzell GA, Haylard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1053–1058
  34. Sebesta M, Cespedes RD, Luhman E, Optenberg S, Thompson IM. Questionnaire-based outcomes of urinary incontinence and satisfaction rates after radical prostatectomy in a national study population. Urology. 2002;60:1055–1058
  35. Twiss C, Slova D, Lepor H. Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology. 2005;66:141–146
  36. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  37. Pavy JJ, Denekamp J, Letschert J, et al. EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys. 1995;31:1043–1047
  38. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management and prevention. Eur Urol. 2006;50:969–979
  39. Seymore CH, el-Mahdi AM, Schellhammer PF. The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. Int J Radiat Oncol Biol Phys. 1986;12:1597–1600
  40. Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys. 2000;48:643–647
  41. Beckendorf V, Guérif S, Le Prisé E, et al. The GETUG 70Gy versus 80Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1056–1065
  42. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007;83:31–41

☆ This work has been sponsored by a scientific grant of the Belgian ‘Foundation against cancer, non profit organization’.

PII: S0167-8140(09)00123-6

doi: 10.1016/j.radonc.2009.03.013

Radiotherapy & Oncology
Volume 92, Issue 1 , Pages 42-47 , July 2009

Article Tools

* Image Usage & Resolution